Sports doping: emerging designer and therapeutic ß2-agonists.
Clin Chim Acta
; 425: 242-58, 2013 Oct 21.
Article
en En
| MEDLINE
| ID: mdl-23954776
Palabras clave
AAF; Beta-agonists; CAS; COMT; COPD; Catechol-O-MethylTransferase; Chronic Obstructive Pulmonary Disease; Court of Arbitration for Sport; Designer drugs; Detection methods; Doping control; ELISA; EU; Enzyme-Linked Immunosorbent Assay; European Union; FDA; Food and Drug Administration; HP-TLC; HRMS; High Performance Thin Layer Chromatography; High Resolution Mass Spectrometry; IAC; ICS; ImmunoAffinity Chromatography; Inhaled Corticosteroid; LABA; LAMA; LCMS; LOD; Limit of Detection; Liquid ChromatographyMass Spectrometry; Long-Acting anti-Muscarinic Agent; Long-Acting ß(2)-Agonist; MIP; MRPL; Minimum Required Performance Limit; Molecular Imprinted Polymer; MonoAmine Oxidase; PCI; Positive Chemical Ionization; RIA; RadioImmunoAssay; SABA; SPE; SPR; Short-Acting ß(2)-Agonist; Solid Phase Extraction; Surface Plasmon Resonance; TLC; TOF; Thin Layer Chromatography; Time-of-Flight; UPLC; UV; Ultra Pressure (or Performance) Liquid Chromatography; Ultraviolet; Veterinary drugs; WADA; World Anti-Doping Agency; adverse analytical finding; ΜΑΟ
Texto completo:
1
Bases de datos:
MEDLINE
Métodos Terapéuticos y Terapias MTCI:
Terapias_biologicas
/
Peloideterapia
Asunto principal:
Drogas de Diseño
/
Suplementos Dietéticos
/
Doping en los Deportes
/
Agonistas de Receptores Adrenérgicos beta 2
/
Antiinflamatorios
Idioma:
En
Revista:
Clin Chim Acta
Año:
2013
Tipo del documento:
Article